FINWIRES · TerminalLIVE
FINWIRES

Citi Downgrades ResMed to Neutral From Buy; Price Target is AU$34

By

ResMed (ASX:RMD) has an average rating of overweight and mean price target of AU$38.72, according to analysts polled by FactSet.

What else is happening in Research?